Detailed Analysis of the Scope and Claims of United States Patent 8,143,239
Introduction
The United States Patent 8,143,239, hereafter referred to as the '239 patent, is one of the key patents held by AstraZeneca AB, particularly relevant to their respiratory drug products such as Symbicort. This patent is part of a broader portfolio that includes other related patents like U.S. Patent Nos. 7,759,328, 8,575,137, and 10,166,247. Here, we will delve into the scope, claims, and the patent landscape surrounding the '239 patent.
Background of the Patent
The '239 patent is directed to formulations of budesonide and formoterol fumarate dihydrate, which are used in the management and treatment of chronic respiratory conditions such as COPD and asthma. These formulations typically include hydrofluoroalkane (HFA) as a propellant, along with polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG) as excipients[2][5].
Patent Claims
The '239 patent includes several claims that define the scope of the invention. Here are some key aspects:
Independent Claims
Independent claim 10 of the '239 patent, for example, specifies the composition and delivery mechanism of the inhalation formulation. It includes the specific concentrations of budesonide and formoterol fumarate dihydrate, as well as the presence of HFA, PVP, and PEG[2].
Dependent Claims
Dependent claims further narrow down the scope by specifying additional limitations. For instance, dependent claim 4 of the '239 patent recites that the PVP is present in the composition at a concentration of 0.001% w/w[2].
Claim Construction and Interpretation
The interpretation of patent claims is crucial in determining the scope of protection. According to the Federal Circuit, the patent specification is the single best guide to the meaning of a disputed term. The specification may reveal a special definition given to a claim term by the patentee that differs from the meaning it would otherwise possess[1].
In the context of the '239 patent, the Federal Circuit has emphasized that the claims should not be limited to the embodiments specifically described in the specification. This means that the invention is not confined to a single embodiment but encompasses a broader scope as defined by the claims[1].
Prosecution History
The prosecution history of the patent is also a critical factor in claim construction. This includes any amendments, arguments, or other communications made during the patent application process. For example, in the case of AstraZeneca v. Mylan, the Federal Circuit used the testing data in the specification, applicant’s amendments, and arguments to narrow the interpretation of a claim term from "0.001%" to a range of "0.00095% to 0.00104%"[5].
Patent Landscape Analysis
A comprehensive patent landscape analysis is essential for understanding the strategic position of the '239 patent within the broader technology area. Here are some key points:
Saturation of the Patent Space
The patent space related to respiratory drug formulations, particularly those involving budesonide and formoterol, is highly saturated. This saturation indicates a competitive and mature technology area where it may be challenging to secure new patents without significant innovation[3].
Competitor Analysis
AstraZeneca is a major player in this space, with multiple patents listed in the U.S. FDA “Orange Book” covering their Symbicort products. Other companies, such as Mylan, have also been involved in litigation and development of generic versions of these products[2][5].
Patent Expiration and Maintenance
The '239 patent is scheduled to expire on April 29, 2024. This expiration date is critical for both AstraZeneca and potential generic manufacturers, as it marks the end of AstraZeneca’s exclusive rights to the formulation[4].
Litigation and Infringement
The '239 patent has been involved in several litigation cases, notably against Mylan Pharmaceuticals. AstraZeneca alleged that Mylan’s filing of an abbreviated new drug application (ANDA) for generic versions of Symbicort infringed upon their patents, including the '239 patent. The litigation has centered around issues of claim construction, validity, and the applicability of the Hatch-Waxman Act[2][5].
Strategic Insights
A patent landscape analysis provides strategic insights that can guide business and R&D decisions. For instance:
-
Entry into a Saturated Market: Companies considering entry into this market need to be aware of the high level of patent saturation and the competitive landscape. This may necessitate a focus on innovative technologies or alternative formulations to avoid infringement issues[3].
-
Long-term Decisions: The analysis helps in making long-term decisions about whether to continue research and development in a particular technology area or to pivot to newer inventive spaces due to high patent saturation[3].
Key Takeaways
- The '239 patent is part of AstraZeneca’s portfolio related to budesonide and formoterol formulations.
- The patent claims are interpreted in light of the specification and prosecution history.
- The patent space is highly saturated, indicating a competitive and mature technology area.
- Patent expiration dates and ongoing litigation are critical factors in the strategic management of these patents.
- Comprehensive patent landscape analysis is essential for making informed business and R&D decisions.
FAQs
Q: What is the primary use of the formulation described in the '239 patent?
A: The formulation is used for managing and treating chronic respiratory conditions such as COPD and asthma.
Q: What are the key components of the formulation described in the '239 patent?
A: The formulation includes budesonide, formoterol fumarate dihydrate, HFA as a propellant, and PVP and PEG as excipients.
Q: When is the '239 patent scheduled to expire?
A: The '239 patent is scheduled to expire on April 29, 2024.
Q: What is the significance of the prosecution history in claim construction?
A: The prosecution history, including amendments and arguments, helps in interpreting the claims and can narrow down the scope of the invention.
Q: Why is patent landscape analysis important for companies in this technology area?
A: Patent landscape analysis helps companies understand the competitive landscape, identify potential risks and opportunities, and make informed decisions about research, development, and patent strategy.
Sources
- Astrazeneca AB v. Mylan Pharm. Inc. - Casetext
- AstraZeneca AB v. Mylan Pharm., Civil Action 1:22-CV-35 - Casetext
- Patent Landscape Analysis - Uncovering Strategic Insights - AcclaimIP
- Drug Patents containing Budesonide; Formoterol Fumarate Dihydrate - Pharsight
- Explicit and Implicit Statements — What You Say Can and Will Be - VK Law
